Contrary to the most commonly cited cost, a new study at JAMA Internal Medicine finds that the cost of developing a cancer drug is around $650 million and that companies typically fully recover that cost within a couple of years after approval.
http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2653012A paper from Stanford University researchers tests various models for improving prediction of who will be a high-cost patients.
Read More
98point6 raises a hot $19.5 million from feverish investors. I am not sure what it does but the geniuses who wrote the press release say the company has an "audacious vision". It uses "deep technology" (on the ocean floor?) to do something related to continuity of care at a "massively lower cost than anything in the market today" (I didn't know cost had mass.) It is not a good sign when you can't tell in the first sentence or two of a press release what a company actually does. These investors are truly delirious.
http://www.businesswire.com/news/home/20170919005623/en/98point6-Raises-19.5-Million-Series-Funding-“ContinuityA report from Mark Farrah Associates looks at mid-year financial performance for health insurers.
Read More
A Genworth Financial report explores cost trends in the costs of long-term care.
Read More
A survey of consumers and physicians gives their perspectives on the causes of rising health costs.
Read More